{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.7","upperLimit":"62.1","value":"46.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"sCR/CR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.6","upperLimit":"60.0","value":"44.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"MRDnegCR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"34.6","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"nCR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.6","upperLimit":"96.3","value":"89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"≥VGPR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.2","upperLimit":"99.9","value":"97.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"ORR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.7","upperLimit":"62.1","value":"46.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"sCR after 8 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"76.2","value":"62.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"sCR/CR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.3","upperLimit":"74.3","value":"60.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"sCR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11.8","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.7","upperLimit":"68.8","value":"53.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"MRDnegCR after 1 year'"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"24.1","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"nCR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.6","upperLimit":"96.3","value":"89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"≥VGPR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.2","upperLimit":"99.9","value":"97.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"ORR after 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.8","upperLimit":"78.1","value":"64.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"sCR/CR after 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"76.2","value":"62.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"sCR after 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11.8","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CR after 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.1","upperLimit":"62.8","value":"46.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"MRDnegCR after 2 years*"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"24.1","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"nCR after 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.8","upperLimit":"97.5","value":"91.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"≥VGPR after 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.2","upperLimit":"99.9","value":"97.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"ORR after 2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Response is assessed by the International Myeloma Working Group Criteria. MRD is defined by M-spike, plasma cell burden, and abnormal free light chains (FLC). Complete response is negative immunofixation on serum, and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) is normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. Near complete response (nCR) is the absence of myeloma protein on electrophoresis, independent of immunofixation status. Very good partial response (VGPR) is serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100mg per 24h. Overall response rate (ORR) is patients who attained a partial response (PR) (≥50% reduction of serum M-protein and reduction in 24h urinary M-protein) or better (BoR) response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year Carfilzomib: Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16 Lenalidomide: Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year Dexamethasone: Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22,","id":"OG000","title":"Carfilzomib, Lenalidomide, and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"\\*Six patients withdrew from the study, four due to non-compliance and two to continue treatment at another institution. 'One patient refused to have a bone marrow biopsy procedure and one patient withdrew due to non-compliance. CR (n=0) after 8 cycles.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Complete Response (CR) and Minimal Residual Disease Neg (MRDneg) CR Rates at Treatment Intervals With Carfilzomib, Lenalidomide & Dexamethasone (CRd) in New Multiple Myeloma Patients After 8 Cycles of Induction, 1 Year Maintenance, and 2 Years Maintenance","type":"SECONDARY","unitOfMeasure":"percentage of participants"}